Enovis Corporation/$ENOV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Ticker
$ENOV
Sector
Primary listing
NYSE
Industry
Health Care Equipment and Supplies
Headquarters
Employees
7,367
Website
ENOV Metrics
BasicAdvanced
$1.6B
-
-$14.50
1.81
-
Price and volume
Market cap
$1.6B
Beta
1.81
52-week high
$49.38
52-week low
$25.93
Average daily volume
1.7M
Financial strength
Current ratio
2.552
Quick ratio
0.993
Long term debt to equity
54.068
Total debt to equity
55.677
Interest coverage (TTM)
0.51%
Profitability
EBITDA (TTM)
323.31
Gross margin (TTM)
58.42%
Net profit margin (TTM)
-37.65%
Operating margin (TTM)
1.88%
Effective tax rate (TTM)
-1.26%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
0.49%
Return on equity (TTM)
-27.35%
Valuation
Price to revenue (TTM)
0.715
Price to book
0.6
Price to tangible book (TTM)
-3.42
Price to free cash flow (TTM)
-39.424
Free cash flow yield (TTM)
-2.54%
Free cash flow per share (TTM)
-69.86%
Growth
Revenue change (TTM)
18.32%
Earnings per share change (TTM)
860.33%
3-year revenue growth (CAGR)
12.99%
10-year revenue growth (CAGR)
-7.08%
3-year earnings per share growth (CAGR)
124.79%
10-year earnings per share growth (CAGR)
4.30%
Bulls say / Bears say
Enovis Corporation reported an 8% increase in first-quarter 2025 sales, with Reconstructive sales growing by 11% year-over-year, indicating strong demand for their orthopedic products. (globenewswire.com)
The company raised its full-year 2025 revenue guidance to approximately $2.22-2.25 billion, reflecting confidence in sustained growth and market expansion. (stocktitan.net)
Analysts have set an average target price of $56.50 for Enovis stock, suggesting a potential upside of 71.78% from its current price, indicating strong market confidence. (directorstalkinterviews.com)
Enovis reported a net loss from continuing operations of $56 million in the first quarter of 2025, highlighting ongoing profitability challenges. (stocktitan.net)
The company's operating margin declined to -8.4% in Q1 2025, down from -6.8% in the same quarter last year, indicating worsening operational efficiency. (stockstory.org)
D. E. Shaw & Co. Inc. reduced its stake in Enovis by 89.9% during the fourth quarter, potentially signaling decreased confidence from institutional investors. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enovis Corporation stock?
Enovis Corporation (ENOV) has a market cap of $1.6B as of July 28, 2025.
What is the P/E ratio for Enovis Corporation stock?
The price to earnings (P/E) ratio for Enovis Corporation (ENOV) stock is 0 as of July 28, 2025.
Does Enovis Corporation stock pay dividends?
No, Enovis Corporation (ENOV) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Enovis Corporation dividend payment date?
Enovis Corporation (ENOV) stock does not pay dividends to its shareholders.
What is the beta indicator for Enovis Corporation?
Enovis Corporation (ENOV) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.